STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Purchases 259,616 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 259,616 shares of the business’s stock in a transaction dated Wednesday, February 12th. The stock was acquired at an average cost of $14.96 per share, for a total transaction of $3,883,855.36. Following the purchase, the insider now owns 11,137,623 shares in the company, valued at approximately $166,618,840.08. This trade represents a 2.39 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The stock was acquired at an average cost of $15.49 per share, for a total transaction of $565,880.68.
• On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The stock was acquired at an average cost of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. bought 21,155 shares of STAAR Surgical stock. The stock was acquired at an average cost of $21.46 per share, for a total transaction of $453,986.30.
• On Wednesday, December 18th, Broadwood Partners, L.P. bought 23,000 shares of STAAR Surgical stock. The stock was acquired at an average cost of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. bought 53,500 shares of STAAR Surgical stock. The stock was acquired at an average cost of $24.24 per share, for a total transaction of $1,296,840.00.

STAAR Surgical Price Performance

Shares of STAA stock opened at $15.35 on Friday. The firm has a market cap of $756.45 million, a P/E ratio of 34.89 and a beta of 0.62. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68. The firm has a fifty day moving average of $23.37 and a two-hundred day moving average of $28.97.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in STAA. Truist Financial Corp acquired a new position in STAAR Surgical during the 2nd quarter worth $268,000. Cetera Investment Advisers acquired a new position in STAAR Surgical during the 2nd quarter worth $1,135,000. Exchange Traded Concepts LLC grew its holdings in STAAR Surgical by 17.6% during the 3rd quarter. Exchange Traded Concepts LLC now owns 30,020 shares of the medical instruments supplier’s stock worth $1,115,000 after acquiring an additional 4,498 shares in the last quarter. Creative Planning boosted its holdings in shares of STAAR Surgical by 8.0% in the 3rd quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock valued at $205,000 after buying an additional 408 shares during the period. Finally, nVerses Capital LLC boosted its holdings in shares of STAAR Surgical by 78.3% in the 3rd quarter. nVerses Capital LLC now owns 4,100 shares of the medical instruments supplier’s stock valued at $152,000 after buying an additional 1,800 shares during the period. 96.70% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

STAA has been the subject of a number of recent analyst reports. BTIG Research lowered shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday. Canaccord Genuity Group lowered their price target on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a report on Thursday. Stephens reaffirmed an “equal weight” rating and set a $28.00 price target on shares of STAAR Surgical in a report on Wednesday. Jefferies Financial Group lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $26.86.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.